Journal
EPILEPSIA
Volume 52, Issue -, Pages 2-26Publisher
WILEY
DOI: 10.1111/j.1528-1167.2011.03121.x
Keywords
Epidemiology; Surveillance; Epilepsy
Categories
Funding
- Kedrion Pharma Company
- Eisai
- Sanofi-Aventis
- UCB Pharma
- GlaxoSmithKline
- UCB
- Dow Agro Science
- Ovation Pharmaceuticals
- Pfizer
- General Electric
- Amgen Inc.
- Genzyme
- Eli Lilly and Company
- Bristol Meyers Squibb
- Boerhringer-Ingelheim
- Astra Zeneca
- Cyberonics
- Esai
- Ortho McNeil
- Janssen-Gilag
- Novartis
Ask authors/readers for more resources
Worldwide, about 65 million people are estimated to have epilepsy. Epidemiologic studies are necessary to define the full public health burden of epilepsy; to set public health and health care priorities; to provide information needed for prevention, early detection, and treatment; to identify education and service needs; and to promote effective health care and support programs for people with epilepsy. However, different definitions and epidemiologic methods complicate the tasks of these studies and their interpretations and comparisons. The purpose of this document is to promote consistency in definitions and methods in an effort to enhance future population-based epidemiologic studies, facilitate comparison between populations, and encourage the collection of data useful for the promotion of public health. We discuss: (1) conceptual and operational definitions of epilepsy, (2) data resources and recommended data elements, and (3) methods and analyses appropriate for epidemiologic studies or the surveillance of epilepsy. Variations in these are considered, taking into account differing resource availability and needs among countries and differing purposes among studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available